Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:1353-1360
Published online before print March 6, 2006, doi: 10.1161/CIRCULATIONAHA.105.575589
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
113/10/1353    most recent
CIRCULATIONAHA.105.575589v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koka, V.
Right arrow Articles by Lan, H. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koka, V.
Right arrow Articles by Lan, H. Y.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Other diabetes
Right arrow Mechanism of atherosclerosis/growth factors
Right arrow Pathophysiology
Right arrow Other arteriosclerosis
Right arrowRelated Article

(Circulation. 2006;113:1353-1360.)
© 2006 American Heart Association, Inc.


Vascular Medicine

Advanced Glycation End Products Activate a Chymase-Dependent Angiotensin II–Generating Pathway in Diabetic Complications

Vijay Koka, MD; Wansheng Wang, MD; Xiao Ru Huang, MD, PhD; Shokei Kim-Mitsuyama, MD; Luan D. Truong, MD; Hui Y. Lan, MD, PhD

From the Department of Medicine–Nephrology, Baylor College of Medicine, Houston, Tex (V.K., W.W., X.R.H., H.Y.L.); Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan (S.K.-M.); and Department of Pathology, Methodist Hospital, Houston, Tex (L.D.T.).

Correspondence to Hui Y. Lan, MD, PhD, Department of Medicine, Section of Nephrology, Baylor College of Medicine, One Baylor Plaza, Alkek N520, Houston, TX 77030. E-mail hlan{at}bcm.tmc.edu

Received July 12, 2005; revision received November 23, 2005; accepted January 6, 2006.

Background— Angiotensin II is a key mediator of diabetes-related vascular disease. It is now recognized that in addition to angiotensin-converting enzyme, chymase is an important alternative angiotensin II–generating enzyme in hypertension and diabetes. However, the mechanism of induction of chymase in diabetes remains unknown.

Methods and Results— Here, we report that chymase is upregulated in coronary and renal arteries in patients with diabetes by immunohistochemistry. Upregulation of vascular chymase is associated with deposition of advanced glycation end products (AGEs), an increase in expression of the receptor for AGEs (RAGE), and activation of ERK1/2 MAP kinase. In vitro, AGEs can induce chymase expression and chymase-dependent angiotensin II generation in human vascular smooth muscle cells via the RAGE-ERK1/2 MAP kinase–dependent mechanism. This is confirmed by blockade of AGE-induced vascular chymase expression with a neutralizing RAGE antibody and an inhibitor to ERK1/2 and by overexpression of the dominant negative ERK1/2. Compared with angiotensin-converting enzyme, chymase contributes to the majority of angiotensin II production (>70%, P<0.01) in response to AGEs. Furthermore, AGE-induced angiotensin II production is blocked by the anti-RAGE antibody and by inhibition of ERK1/2 MAP kinase activities.

Conclusions— AGEs, a hallmark of diabetes, induce chymase via the RAGE-ERK1/2 MAP kinase pathway. Chymase initiates an important alternative angiotensin II–generating pathway in diabetes and may play a critical role in diabetic vascular disease.


 

CLINICAL PERSPECTIVE


Related Article:

Issue Highlights
Circulation 2006 113: 1271. [Full Text]



This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
V. Koka, X. R. Huang, A. C.K. Chung, W. Wang, L. D. Truong, and H. Y. Lan
Angiotensin II Up-Regulates Angiotensin I-Converting Enzyme (ACE), but Down-Regulates ACE2 via the AT1-ERK/p38 MAP Kinase Pathway
Am. J. Pathol., May 1, 2008; 172(5): 1174 - 1183.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama
The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease
Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. N. Lavrentyev, A. M. Estes, and K. U. Malik
Mechanism of High Glucose Induced Angiotensin II Production in Rat Vascular Smooth Muscle Cells
Circ. Res., August 31, 2007; 101(5): 455 - 464.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. P. Singh, B. Le, V. B. Bhat, K. M. Baker, and R. Kumar
High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H939 - H948.
[Abstract] [Full Text] [PDF]